Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis

Upadhyay, Ashish, Earley, Amy, Lamont, Jenny L., Haynes, Shana, Wanner, Christoph, Balk, Ethan M. · 2012 · Annals of Internal Medicine

Abstract

BACKGROUND: Lipid-lowering therapy is not widely used in persons with chronic kidney disease (CKD) despite a high burden of dyslipidemia and cardiovascular disease in this population. PURPOSE: To synthesize evidence examining the effect of lipid-lowering therapy on clinical outcomes in persons with CKD. DATA SOURCES: MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from January 2000 through November 2011. STUDY SELECTION: Randomized, controlled trials (RCTs) comparing lipid-lowering therapy with control treatment in persons with CKD, including subgroup analyses of trials in the general population. DATA EXTRACTION: Abstracts were screened and data were extracted on study methodology, population, interventions, cardiovascular and kidney outcomes, and adverse events. Data were extracted by one author and confirmed by another. Study quality was determined by consensus. Random-effects model meta-analyses were performed. DATA SYNTHESIS: 18 RCTs, all in adults, met the eligibility criteria. Five RCTs involved CKD populations, and 13 were CKD subgroup analyses from trials in the general population. Sixteen RCTs examined statins, and 2 examined statins plus ezetimibe. Lipid-lowering therapy does not improve kidney outcomes but decreases the risk for cardiac mortality (pooled risk ratio [RR] from 6 trials, 0.82 [95% CI, 0.74 to 0.91]; P< 0.001), cardiovascular events (including revascularization) (pooled RR from 9 trials, 0.78 [CI, 0.71 to 0.86]; P< 0.001), and myocardial infarction (pooled RR from 9 trials, 0.74 [CI, 0.67 to 0.81]; P< 0.001). Significant benefit was also seen for all-cause mortality but was limited by a high degree of heterogeneity. No benefit was found for other cardiovascular outcomes. Rates of adverse events were similar between intervention and comparator groups. LIMITATIONS: Lack of data in children, heterogeneity among reviewed studies, and the possibility of selective reporting of outcomes and adverse events. CONCLUSION: Lipid-lowering therapy decreases cardiac death and atherosclerosis-mediated cardiovascular events in persons with CKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-157-4-201208210-00005

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 166

Metadata

Authors
Upadhyay, A., Earley, A., Lamont, J. L., Haynes, S., Wanner, C., & Balk, E. M.
Venue
Annals of Internal Medicine
Published
2012-08-21
Volume
157
Issue
4
Pages
251-262
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2036961560
Cited by
166
References
14
FWCI
27.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.7326/0003-4819-157-4-201208210-00005
The paper
Upadhyay, A., Earley, A., Lamont, J. L., Haynes, S., Wanner, C., & Balk, E. M. (2012). Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-157-4-201208210-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.